Front Page News
Administration Officials & Members of Congress Highlight SMA Community Advocacy at 12th Annual Hope on the Hill Washington, D.C. Event
Two high-ranking Administration officials and several Members of Congress from key congressional committees participated in Cure SMA’s November 29th Hope on the Hill dinner and […]
Read More ›Sweet Success: Baking a Difference Returns for a Second Year
Breaking and Baking News! Get ready to dust off those aprons and preheat those ovens because Baking a Difference is back and better than […]
Read More ›Biogen Shares DEVOTE and RESPOND Study Updates
Biogen recently shared that they have completed enrollment in the global DEVOTE and RESPOND clinical studies. Check out the full SMA Community Statement here.
Read More ›Genentech Shares 1-Year Primary Analysis from RAINBOWFISH
Last week, Genentech, a member of the Roche Group, presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and […]
Read More ›Novartis Gene Therapies SMA Community Update
Dear SMA Community, It was a pleasure to be able to join so many of you at the Cure SMA Annual Conference in Orlando this […]
Read More ›Cure SMA on Capitol Hill – A Message from Allie Williams
Hey, it’s Allie here from Oklahoma! I am privileged to serve on the Cure SMA Adult Advisory Council and am part of a group of […]
Read More ›SMA Highlights and Updates from Biogen
Dear SMA Community, As we reflect on SMA Awareness Month, we take this opportunity to celebrate all those who are a part of the SMA […]
Read More ›Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
An important part of Cure SMA’s core mission is to carry out and support research that will improve the quality of life for all people […]
Read More ›NMD Pharma Initiates Phase II Trial for SMA
NMD Pharma, a clinical-stage biotech company leading the development of novel first-in-class therapies for severe neuromuscular disorders, recently announced that the first SMA patient has […]
Read More ›Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
Today, Scholar Rock announced that enrollment in their Phase 3 SAPPHIRE trial is now complete. The Phase 3 trial will evaluate the safety and efficacy of […]
Read More ›